Laquinimod Sodium

拉喹莫德钠

Report date: 2025/12/17 10:52:06
NME

Base Information

Drug NameLaquinimod Sodium
Drug Alias NameLaquinimodum拉喹莫德NerventraTV-5600ABR-215062 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBrain-derived neurotrophic factor expression stimulantsAryl hydrocarbon receptor agonists
TargetsBrain-derived neurotrophic factorAryl hydrocarbon receptor
Therapy Area/IndicationsLupus NephritisUveitisEye Diseases +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBosnia and Herzegovina +[38] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesActive Biotech Ab
China Registration ClassN/A

Develop Information

Active CompaniesActive Biotech Ab
Inactive CompaniesTeva Pharmaceuticals International GmbhTeva Generics GmbhTeva Branded Pharmaceutical Products R&D Inc +[4] 
Active IndicationsUveitisEye Diseases
Inactive IndicationsLupus NephritisHuntington DiseaseMultiple Sclerosis, Relapsing-Remitting +[7] 

Other Information

ATC CodeN07XX10
Related LinksWikipediaDrugBankKEGG